An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Bayer
- Enrolment target
- 600
- Started
- 25 September 2024
- Main results due
- 31 March 2028
- Study sites
- 1
- Registry updated
- 23 September 2026
Can you take part?
- Aged 19 years and over.
- Men only.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Male aged ≥19 years * Patients with high risk nmCPRC * Castrate level of serum testosterone (\< 1.7 nmol/l \[50 ng/dL\]) * PSA doubling time \< 10 months * Patients with mHSPC * histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI). * be candidates for androgen-deprivation therapy with/without docetaxel. * Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice * Written informed consent from subject or legal representative; assent from subject when appropriate Exclusion Criteria: * Patients participating in an investigational program with interventions outside of routine clinical practice * Participants with contraindication according to the locally approved prescribing information
What this study is about
In the sponsor’s own words, from the registry.
This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.
This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.
To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.
During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.
Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.
Study sites(1)
Many locations
Multiple Locations, South Korea
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06334120. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me